Predictive factors of the pharmacological action of tolvaptan in patients with liver cirrhosis: a post hoc analysis.

ABSTRACT:

Background

Tolvaptan has been approved in Japan for the treatment of hepatic edema. An important consideration in providing a clinical benefit to patients with liver cirrhosis is the improvement of ascites-related clinical symptoms. In the present post hoc analysis, we aimed to identify factors that were predictive of the potency of tolvaptan, and to examine the relationship between changes in initial urine volume and improvement in ascites-related clinical symptoms.

Methods

This post hoc analysis was based on three previous phase 2 and 3 clinical trials of tolvaptan in patients with liver cirrhosis. Predictive factors associated with a change in initial urine volume were identified. A change of ≥500 mL from baseline confirmed the pharmacological action of tolvaptan treatmen

SUBMITTER: Sakaida I 

PROVIDER: S-EPMC5281662 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature